Immunovia AB (publ) (STO:IMMNOV)
Sweden · Delayed Price · Currency is SEK | Market Cap | 54.35M -46.2% |
| Revenue (ttm) | 1.21M +31.8% |
| Net Income | -88.34M |
| EPS | -0.16 |
| Shares Out | 672.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,951,187 |
| Open | 0.0815 |
| Previous Close | 0.0886 |
| Day's Range | 0.0800 - 0.0879 |
| 52-Week Range | 0.0600 - 0.3555 |
| Beta | 2.73 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Immunovia AB
Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden. [Read more]
Financial Performance
In 2025, Immunovia AB's revenue was 685,000, a decrease of -26.42% compared to the previous year's 931,000. Losses were -145.92 million, 90.6% more than in 2024.
Financial StatementsNews
Immunovia AB Earnings Call Transcript: Q2 2026
PancreaSure adoption expanded to 27 high-risk programs, driving over 300% sales growth year-over-year. Cash burn remains below guidance, with operations funded into Q4 2026. Medicare and New York State coverage submissions are key near-term catalysts.
Immunovia AB Quarterly report: Q2 2026
Immunovia AB has published its Q2 2026 quarterly earnings report on August 6, 2026.
Immunovia AB Slides: Q2 2026
Immunovia AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Immunovia AB Earnings Call Transcript: Q1 2026
Q1 2026 saw 169% revenue growth and improved operating loss, driven by increased PancreaSure adoption and disciplined cost control. Strategic focus remains on expanding U.S. market penetration, securing reimbursement, and forming commercialization partnerships, with a strong cash position supporting operations through Q3 2026.
Immunovia AB Quarterly report: Q1 2026
Immunovia AB has published its Q1 2026 quarterly earnings report on May 7, 2026.
Immunovia AB Slides: Q1 2026
Immunovia AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Immunovia AB Earnings Call Transcript: Q4 2025
PancreaSure launched in Q4 2025 with early adoption at 12 centers and strong clinical validation. Revenue remains modest, but a SEK 69.8 million rights issue extends cash runway through Q3 2026. Medicare coverage submission is planned for mid-2026, with significant revenue expected in 2027.
Immunovia AB Annual report: Q4 2025
Immunovia AB has published its Q4 2025 annual report on February 24, 2026.
Immunovia AB Quarterly report: Q4 2025
Immunovia AB has published its Q4 2025 quarterly earnings report on February 24, 2026.
Immunovia AB Slides: Q4 2025
Immunovia AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 24, 2026.
Immunovia AB Earnings Call Transcript: Q3 2025
PancreaSure's commercial launch marked a major milestone, with rapid adoption by leading cancer centers and strong clinical validation. Financial discipline reduced cash burn, and a successful rights issue secured funding into 2026. Medicare reimbursement progress and further clinical studies are key next steps.
Immunovia AB Quarterly report: Q3 2025
Immunovia AB has published its Q3 2025 quarterly earnings report on November 26, 2025.
Immunovia AB Slides: Q3 2025
Immunovia AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 26, 2025.
Onconetix’s Proteomedix licenses manufacturing IP to Immunovia
Onconetix (ONCO) announced that its wholly owned subsidiary, Proteomedix has signed a licensing agreement, with Immunovia (IMMVF), a pancreatic cancer diagnostics company based in Lund, Sweden. Under ...
Immunovia AB Earnings Call Transcript: Q2 2025
PancreaSure's launch marks a pivotal step, with strong scientific validation and initial adoption by top U.S. centers. Q2 saw reduced expenses and a successful rights issue to fund commercialization and reimbursement studies, with revenue expected to shift from patient pay to insurance by 2027.
Immunovia AB Slides: Q2 2025
Immunovia AB has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 28, 2025.
Immunovia AB Quarterly report: Q2 2025
Immunovia AB has published its Q2 2025 quarterly earnings report on August 28, 2025.
Immunovia AB Earnings Call Transcript: Q1 2025
Transitioning to commercialization, the PancreaSure test is set for a September 2025 launch, showing strong clinical performance and doubling its addressable market. Cash reserves are expected to last through Q3, with ongoing efforts to secure partnerships and reimbursement.
Immunovia AB Quarterly report: Q1 2025
Immunovia AB has published its Q1 2025 quarterly earnings report on May 14, 2025.
Immunovia AB Slides: Q1 2025
Immunovia AB has posted slides in relation to its Q1 2025 quarterly earnings report, which was published on May 14, 2025.
Immunovia publishes the Annual Report for 2024
LUND, Sweden , April 2, 2025 /PRNewswire/ -- Immunovia AB (publ) today announced that the Annual Report for 2024 has been published. The annual report can be downloaded in pdf format and is available ...
Immunovia provides further data from VERIFI study of pancreatic cancer test
Immunovia (IMMVF) announced additional results from the VERIFI study of its next-generation pancreatic cancer test. Immunovia’s next-generation test detected significantly more cancers than CA19-9, a ...
Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test
LUND, Sweden , March 24, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of it...
Immunovia AB Transcript: Study update
A clinical validation study in high-risk individuals showed a next-generation blood test detects early-stage pancreatic cancer with 77% sensitivity and 88% specificity, outperforming standard imaging and CA 19-9. Combined with prior data, results support reimbursement, regulatory approval, and a targeted US launch in Q3 2025.
Immunovia AB Press release: Study update
Immunovia AB issued a press release on March 24, 2025, disclosing material business information to investors.